SynthesisJournal of neurology2026
Central vein sign and paramagnetic rim lesions in pediatric-onset multiple sclerosis: a systematic review and meta-analysis.
Synthesis in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSusceptibility-based MRI biomarkers, including paramagnetic rim lesions (PRLs) and central vein sign (CVS), were incorporated into the 2024 McDonald criteria because they improve diagnostic specificity in adult-onset MS; however, their role in pediatric-onset MS (POMS) remains incompletely defined.
objectiveTo synthesize current evidence on the prevalence and diagnostic value of PRLs and CVS in POMS.
methodsWe conducted a PRISMA-compliant systematic review and random-effects meta-analysis of studies reporting PRLs and/or CVS in POMS. Outcomes included the proportion of patients with ≥1 PRL, the mean proportion of CVS-positive lesions, and fulfillment of CVS-based thresholds.
resultsEleven studies were included. Across seven studies, the pooled proportion of POMS patients with ≥1 PRL was 71.6% (95% CI 61.1-80.2; n=149), with low between-study heterogeneity. Across six studies, the pooled mean proportion of CVS-positive lesions was 57.9% (95% CI 39.7-76.2; n=99), and 66.2% (95% CI 10.5-97.0; n=219) of patients fulfilled the 40%-CVS rule, with substantial variability across studies. In comparative analyses, PRLs showed high specificity for POMS, while CVS was more prevalent than in mimics; however, limited data precluded quantitative evaluation.
conclusionPRLs are frequent in POMS. Limited comparative data suggest that PRLs may have high diagnostic specificity, whereas CVS appears more variable; however, pediatric diagnostic accuracy evidence remains scarce. Further pediatric-specific studies are needed to define the optimal diagnostic use of these biomarkers in POMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.